Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.00
- Piotroski Score 2.00
- Grade Buy
- Symbol (ALLO)
- Company Allogene Therapeutics, Inc.
- Price $2.21
- Changes Percentage (4.5%)
- Change $0.1
- Day Low $2.09
- Day High $2.23
- Year High $5.78
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $33.50
- High Stock Price Target $55.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.78
- Trailing P/E Ratio -1.3
- Forward P/E Ratio -1.3
- P/E Growth -1.3
- Net Income $-327,265,000
Income Statement
Quarterly
Annual
Latest News of ALLO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Spanish sailors ride wave of $2M win, Olympic gold medal to lead Los Gallos into SailGP's Season 5
Spanish sailors Diego Botin and Florian Trittel had an exceptional summer in sailing, winning both the SailGP Season 4 championship and an Olympic gold medal. They are now gearing up to defend their t...
By AP NEWS | 1 day ago -
Gordon Brown: improve end-of-life care rather than allow assisted dying
Gordon Brown opposes legalizing assisted dying, advocating for improved end-of-life care instead. Reflecting on his daughter's death, he stresses the importance of palliative care and suggests a 10-ye...
By The Guardian | 1 day ago -
Supreme Court allows multibillion-dollar class action to proceed against Meta
The Supreme Court dismissed Meta's appeal, allowing a lawsuit to proceed. Investors claim Meta failed to disclose risks regarding user data misuse by Cambridge Analytica, leading to share price drops....
By Yahoo! Finance | 1 day ago
